PBAL05 / Passage Bio - LARVOL DELTA

Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021 (GlobeNewswire) - "The company’s additional adult preclinical programs are PBAL05 for amyotrophic lateral sclerosis (ALS)...The company has submitted investigational new drug (IND) applications to FDA for Phase 1/2 clinical studies of PBFT02 in FTD-GRN...The company recently received orphan drug designation from FDA for PBFT02 for FTD-GRN...Passage Bio anticipates the start of both clinical programs in the first half of 2021. Initial data from these trials are anticipated to potentially readout in late 2021 or early 2022, depending on the timing of first patient treated in each study....We have also manufactured clinical supplies to initiate clinical trials for...PBFT02 for FTD-GRN."

IND • New P1/2 trial • Orphan drug • P1/2 data • Amyotrophic Lateral Sclerosis • CNS Disorders • Frontotemporal Lobar Degeneration